What is Humanin?
Humanin is a 24 amino acid peptide encoded by mitochondrial DNA (the separate genetic code inside the cell's energy-producing mitochondria) that was discovered in 2001 as a factor protecting neurons from Alzheimer's disease related toxicity. In rodents it and its potent analogs (modified versions) improve insulin sensitivity, protect the heart and brain from injury, and in mice a humanin analog extended healthspan (years lived in good health); in people, circulating levels fall with age and correlate with coronary endothelial function (how well the lining of the heart arteries works), but no human treatment trial has been published. It has never been reviewed by FDA, is prohibited by WADA under section S0 (the anti-doping ban on unapproved substances), and is not available through licensed channels.
Humanin is a mitochondrial derived peptide (24 amino acids) encoded in the 16S rRNA region of mitochondrial DNA. It is also known as HN, HNG (S14G-humanin analog), MT-RNR2 peptide, Mitochondrial derived peptide humanin, Humanin peptide.
How does it work?
Humanin is translated from a short open reading frame in the mitochondrial 16S rRNA gene (MT-RNR2). Inside cells it binds the pro-apoptotic proteins Bax and IGFBP-3 to block apoptosis. Outside cells it signals through a receptor complex of CNTFR, WSX-1, and gp130 that activates STAT3, and through the formyl peptide receptor-like 1. In rodents, central and peripheral humanin increases hypothalamic STAT3 signaling and improves hepatic insulin sensitivity. Circulating levels decline with age in humans and rodents. Mechanisms are established in cells and animals only.
| Cluster | Longevity and mitochondrial |
|---|---|
| Routes | Subcutaneous injection (as sold); Intraperitoneal and intracerebroventricular injection (animal studies) |
| Conditions studied | Cognitive decline and nootropic use; Longevity and healthy aging; Cardiovascular risk reduction; Insulin resistance and prediabetes; Mitochondrial disease and dysfunction |
| Record | v3, reviewed, verified Sep 29, 2026 |
What does the evidence say about Humanin?
Cell studies show humanin protects neurons from amyloid beta and familial Alzheimer's mutations. Rodent studies show that humanin and its analog HNG improve insulin action, reduce infarct size in heart and brain injury models, and that HNG treatment of middle aged mice improved metabolic healthspan and memory. Human evidence is observational: circulating humanin declines with age, and in 40 patients undergoing coronary testing higher levels were associated with preserved endothelial function. No human intervention trial of humanin or an analog has been published. The human study is an association study of endogenous humanin levels, not an intervention with the peptide; it is listed but does not raise the grade.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 0 | n/a |
| Human observational studies | 1 | 40 |
| Animal studies | 3 | n/a |
| All indexed studies | 4 | 40 |
Human evidence
No indexed human treatment trial identified. Widmer et al. 2013 measured plasma humanin in 40 patients with chest pain and non-obstructive coronary disease and found higher levels in those with normal coronary endothelial function. Yen et al. 2020 reported that circulating humanin declines with age in humans and that levels were higher in the offspring of centenarians, an association study rather than a treatment effect.
Animal evidence
Hashimoto et al. 2001 identified humanin as a factor that rescues cultured neurons from death caused by familial Alzheimer's disease genes and amyloid beta. Muzumdar et al. 2009 showed that central or peripheral humanin and its analog HNG improved hepatic insulin sensitivity in rats through hypothalamic STAT3. Yen et al. 2020 showed that HNG given twice weekly to middle aged mice improved metabolic healthspan and memory without extending mean life span, and that humanin overexpression in worms extended life span.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta2001 PMID 11371646 | Cell culture discovery studyCultured neuronal cells expressing familial Alzheimer's disease mutations or exposed to amyloid beta | Identified humanin as a 24 amino acid peptide that abolished neuronal death caused by familial Alzheimer's disease genes and amyloid beta | Evidence: Animal-only evidence |
| Humanin: a novel central regulator of peripheral insulin action2009 PMID 19623253 | Rat clamp studies with central and peripheral peptide administrationRats | Humanin and its analog HNG improved hepatic insulin sensitivity through hypothalamic STAT3 signaling | Evidence: Animal-only evidence |
| Circulating humanin levels are associated with preserved coronary endothelial function2013 PMID 23220334 | Cross sectional observational studyn = 40 Patients with chest pain and non-obstructive coronary artery disease undergoing endothelial function testing | Higher plasma humanin was associated with normal coronary endothelial function | Evidence: Human observational evidence |
| The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan2020 PMID 32575074 | Worm and mouse treatment studies plus human cohort measurementsC. elegans, middle aged mice, and human cohorts including offspring of centenarians | Humanin overexpression extended worm life span; HNG improved metabolic healthspan and memory in mice; circulating humanin declined with age in humans and was higher in centenarian offspring | Evidence: Animal-only evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Cognitive decline and nootropic use | Not graded | Semax, selank, dihexa, cerebrolysin, and related compounds are marketed for cognition. Cerebrolysin has small clinical trials in stroke and dementia, mostly outside the United States. Semax and selank have Russian clinical literature but no indexed US or EU randomized trials. Dihexa and P21 are animal-only. |
| Longevity and healthy aging | Evidence: Animal-only evidence | Cytoprotective in animal models; no human trials. |
| Cardiovascular risk reduction | Evidence: Animal-only evidence | Higher natural humanin levels tracked with better coronary endothelial function in one small study of 40 patients, but humanin has never been given to people. |
| Insulin resistance and prediabetes | Evidence: Animal-only evidence | Improved hepatic insulin sensitivity in rats through a brain signaling pathway; no human dosing studies. |
| Mitochondrial disease and dysfunction | Evidence: Animal-only evidence | Extended lifespan in worms and improved metabolic healthspan in mice; human data are associations with age only. |
Is Humanin legal in the United States?
FDA and compounding status
Humanin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. Without a listing, a 503A pharmacy has no federal basis to compound it as a bulk substance. It is not eligible for 503B outsourcing. Products sold under this name for human use are unapproved drugs.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
No regulatory events recorded.
Full tracker for Humanin or the category-wide tracker.
Email me when Humanin's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of Humanin used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature. Rodent studies used humanin or HNG in the range of 0.1 to 4 mg/kg by intraperitoneal injection, and 2 to 4 mg/kg HNG twice weekly in the mouse healthspan study. No human dose finding or pharmacokinetic study has been published.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous injection (as sold) |
| 2 | Intraperitoneal and intracerebroventricular injection (animal studies) |
What are the side effects and interactions of Humanin?
Side effects
| # | Reported side effect |
|---|---|
| 1 | No systematic human safety data published |
| 2 | Injection site reactions reported anecdotally |
| 3 | Theoretical concern that an anti-apoptotic, STAT3 activating peptide could support tumor cell survival (not demonstrated in humans) |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal human interaction studies exist |
| 2 | Theoretical additive glucose lowering with insulin or oral diabetes drugs, based on rodent insulin sensitivity data (not tested) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Active cancer or history of cancer (theoretical anti-apoptotic concern) |
| 2 | Pregnancy and breastfeeding (no data) |
| 3 | Competitive athletes subject to WADA testing (prohibited at all times under S0) |
How do people access Humanin legally?
Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Not available
Not legally available: no approved product and no 503A bulks listing.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare Humanin
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names humanin. [9] [10] [11]
Being offered does not change the legal status of humanin. Humanin is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [5] [12]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [9] [12] [13] [14] [15] [16]
What that means for you
- A pharmacy that compounds humanin is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [9] [13]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [16]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [17]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [18] [19]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [12]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, humanin is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [7]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound humanin, with or without a prescription. [5]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [20] [21] [22]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [11] [22] [23]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [16] [24] [25] [26] [27] [28]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [16]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [20]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [11]
- Pharmacy: Is this made for me on a prescription written in my name? [23]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [11] [22]
- Prescriber: What is the legal basis for a pharmacy to compound humanin? Is it FDA approved or on the 503A bulks list? [5] [16]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [11]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [17]
Frequently asked questions
Is humanin legal in the United States?
It is not an FDA approved drug and is not on the FDA 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), so a compounding pharmacy has no federal basis to make it. Possessing it is not a crime, but selling it for human use is unlawful: the only products on the market are research chemicals, which are unapproved drugs. Unlike MOTS-c and epitalon, humanin was not among the peptides FDA presented to the committee in July 2026. [5] [6] [8]
Does humanin protect the brain or prevent Alzheimer's disease?
In cultured neurons and rodents, humanin protects against amyloid beta toxicity and improves memory in treated mice. No human trial has tested whether it prevents or treats Alzheimer's disease or cognitive decline. The human data are limited to blood levels, which fall with age. PeptideAgent grades the evidence animal-only. [1] [4]
Does humanin extend lifespan?
In worms, overexpressing humanin extended life span. In middle aged mice, the analog HNG improved metabolic health and memory but did not extend mean life span. In humans, higher humanin levels were seen in children of centenarians, which is an association, not proof that giving humanin adds years. No human longevity trial exists. [4]
What are the side effects of humanin?
There is no systematic human safety data. Anecdotal reports mention injection site irritation. Because humanin blocks apoptosis and activates STAT3, a theoretical concern is that it could help cancer cells survive; this has not been studied in people. Rodent studies have not reported toxicity at the doses used. [1] [2]
How is humanin taken?
In animal studies it was injected into the abdominal cavity, into the brain, or under the skin. Products sold to people are subcutaneous injection vials. No human dose finding or absorption study exists. PeptideAgent does not give doses for unapproved peptides. [2] [4]
Is humanin banned by WADA?
Yes. Humanin has no current approval from any government health authority for human use, so it falls under section S0 (non-approved substances) of the WADA Prohibited List and is prohibited at all times. [7]
Humanin vs MOTS-c: which has better evidence?
Both are mitochondrial derived peptides with mouse data and human blood level associations only. MOTS-c has the stronger metabolic and exercise data in mice. News reports said the FDA advisory committee voted to recommend listing it in July 2026, but FDA's own briefing recommended against listing, and FDA has not posted the vote or minutes. Humanin has the older neuroprotection literature and a mouse healthspan study but no compounding pathway. Neither has a published human treatment trial. [3] [4] [6]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Hashimoto Y et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A 2001PubMed 11371646, 2001
- [2]Muzumdar RH et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One 2009PubMed 19623253, 2009
- [3]Widmer RJ et al. Circulating humanin levels are associated with preserved coronary endothelial function. Am J Physiol Heart Circ Physiol 2013PubMed 23220334, 2013
- [4]Yen K et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY) 2020PubMed 32575074, 2020
- [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [7]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [8]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [9]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
- [10]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 29). Humanin: evidence, legality, and access. https://peptideagent.ai/peptides/humanin- HTML link
<a href="https://peptideagent.ai/peptides/humanin">Humanin: evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.